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INTRODUCTION
In the last few years, cases of osteonecrosis of the jaw (ONJ) 
have been detected in cancer patients taking bisphosphona-
tes as part of their treatment. The publications and cases 
notified to date mention that the majority of the patients 
were on antineoplastic treatment (chemotherapy, steroids 
treatment, or radiotherapy for head and neck tumors), and 
they were administered bisphosphonates concomitantly for 
the treatment of cancer and its related symptoms, indicating, 
most of  such reports, the appearance of ONJ following 
dental procedures.
Both prevention, as well as diagnosis and treatment of the 
ONJ and other oral complications caused by cancer, should 
be dealt with in an interdisciplinary way, based on the cli-
nical evaluation made by the physician who establishes the 
treatment, as well as by the physician responsible for the 
treatment of the ONJ, according to the possible benefit and 
potential risks of such treatment.
It is important that all physicians involved are sufficiently 
informed about the disease, its symptoms, and the treat-
ments of cancer patients who take bisphosphonates, as well 
as about the most suitable treatment; a good communication 
among them is also important.
Various bibliographic references, guides, and recommen-
dations exist on the prevention, diagnosis, and treatment 
of the ONJ; although due to its low incidence and recent 
appearance, it is an issue still unknown to the majority of 
the physicians. Information available for a better understan-
ding of the pathology and the treatment of patients with 
osteonecrosis of the jaw, as well as its adaptation to the 
Spanish healthcare setting is limited. A panel of Spanish 
experts representing the specialties of Medical Oncology, 
Hematology, Urology, and Stomatology, has recently held 
a meeting to debate on and identify the risk factors associa-
ted with the osteonecrosis of the jaw, as well as to develop 
some clinical guidelines on the prevention, early diagnosis, 
management, and interdisciplinary treatment of such pa-
thology, in patients with advanced malignancies with bone 
affectation, treated with bisphosphonates.
The experts panel developed various documents to faci-
litate the physicians’ orientation in the treatment of their 
patients.
1. Recommendations document for cancer patients treated 
with bisphosphonates, including the following aspects:
a. Consensus on the definition of the ONJ.
b. Preventive measures.
c. Action plan in case of ONJ suspicion.
d. ONJ treatment.
e. Recommendations on the use of  bisphosphonates in 
patients with malignancies.
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f. Reasons for using bisphosphonates.
2. Referral Sheet
Given that both the consensus document and the bisphos-
phonates technical file recommend that patients should be 
evaluated by an odontologist / stomatologist before and 
during the treatment with bisphosphonates, a consensus 
has been reached to develop a referral sheet with all indis-
pensable data in order to facilitate such process.
3) ONJ Register Sheet
This document contains the data necessary (risk factors, 
treatments administered, dental procedures, bisphosphona-
tes regimens and doses) to carry out a study of ONJ causes 
in this kind of patients.
DIAGNOSTIC CRITERIA FOR BISPHOSPHO-
NATES-RELATED OSTEONECROSIS OF THE 
JAW (ONJ)
1. A patient who is or has been taking bisphosphonates due 
to suffering a malignancy.
2. Presence of  one or various ulcers in the mucosa of 
the alveolar processes, with exposure of the maxillary or 
mandibular bone.
3. The bone observed at the bottom of the ulceration looks 
like a necrotic bone.
4. The lesion is produced either spontaneously or, most 
often, after a dental surgery or procedure (especially dental 
extractions).
5. Absence of  cicatrisation during a minimum six-week 
period; on the contrary, in most cases, the lesion progresses, 
causing bone exposure expansion and pain increase.
IN CASE OF A CLINICAL SUSPICION OF ONJ
Refer patients to the hospital where they are treated of their 
neoplastic problem, in order to confirm the ONJ diagnosis 
and establish a suitable treatment.
1. PREVENTIVE MEASURES TO BE TAKEN BY 
THE ODONTOLOGIST OR STOMATOLOGIST, 
OR BOTH, FOR PATIENTS TREATED WITH 
BISPHOSPHONATES WITHOUT ONJ
1.A. BEFORE INITIATING BISPHOSPHONATES 
TREATMENT
All patients with concomitant risk factors (e.g.. cancer, 
chemotherapy, corticosteroids), who are going to begin 
a treatment with bisphosphonates, should consider being 
examined by their Odontologist / Stomatologist, before 
initiating the treatment; the physician should take into 
account the following recommendations:
- It is very important to detect possible infection sources in 
the patient, both already existing, as well as potential ones 
and, if  any, to eliminate them before initiating bisphospho-
nates treatment.
- Those teeth that, due to periodontal pathologies, is not 
quite clear that could be subsequently maintained, should 
be extracted before the commencement of the bisphospho-
nates treatment.
The specialist treating the patient’s cancer should bear in 
mind the following recommendations:
- To inform patients and their families about the necessary 
buccal care. 
- To inform patients that they notify the specialist treating 
their cancer of the appearance of any buccal problems or 
any odontological procedures (including dental extraction). 
In this case, the patient should be referred to the odonto-
logist / stomatologist, who will proceed in accordance with 
the recommendations.
1.B. DURING BISPHOSPHONATES TREATMENT
During bisphosphonates treatment, it is recommended 
that the patient visits an odontologist / stomatologist, at 
least once a year, to detect and, if  any, to treat caries and 
periodontal diseases at an early stage. To this end, it is 
recommended to:
- Explore teeth to detect and treat caries. It is advisable 
to proceed to obturations and endodontics, avoiding any 
“dental extractions” due to caries during bisphosphonates 
treatment.
- Explore the periodontal area and, subsequently, eliminate 
plaque and periodontal pouches, to avoid the need of a teeth 
extraction in the future due to this kind of problems.
- Avoid friction lesions (chronic traumatisms), paying special 
attention to prostheses.
1.C. IN CASE OF EXTRACTION DURING BISPHOS-
PHONATES TREATMENT
In case of a patient treated with bisphosphonates, it has 
been already mentioned that, whenever possible, “dental 
extractions” should be avoided, although if  it is absolutely 
necessary to perform an extraction the following recom-
mendations should be taken into account:
- Perform the extraction in the less traumatic way possible. 
Residues of large alveolar bone defects should be avoided, 
and, of course, the possibility of conducting an alveolus 
suture to facilitate subsequent cicatrisation should be 
evaluated.
- Administrating oral amoxicillin / clavulanic acid (875 mg 
/ 125 mg three times a day) or clindamycin (300 mg / 3-4 
times a day) two days prior to the extraction, and during 
ten days after the extraction.
- Following the extraction, the patient should rinse with 
0.12% chlorhexidine, twice a day for 15 days.
- Reviewing the evolution of the procedure by the stoma-
tologist.
- The possibility to temporarily suspend the bisphosphona-
tes treatment (2-3 months prior to the procedure, and until 
the lesion cicatrisation has been confirmed), is up to the 
physician, since there is no evidence of the benefit of such 
interruption and lesions without osteonecrosis.
2. ACTION PLAN IN CASE OF A CANCER PATIENT 
WITH A SUSPICION OF OSTEONECROSIS OF 
THE JAW (ONJ)
The above-mentioned recommendations should be follo-
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wed for areas without osteonecrosis, with regards to dental 
plaque, caries and periodontal pathology.
2.A. DIAGNOSIS OF THE OSTEONECROSIS AREA (S).
A.1. Clinical diagnosis
- Presence of one or various ulcers in the mucosa of the 
alveolar processes, with exposure of  the maxillary or 
mandibular bone.
- The bone observed at the bottom of the ulceration looks 
like a necrotic bone.
- Absence of cicatrisation during a minimum six-week pe-
riod; on the contrary, in most cases, the lesion progresses, 
thus bone exposure expands and pain increases.
.A.2. Diagnosis based on complementary tests 12.506.
- Request an orthopantograph.
- Request a CAT scan, which will determine and evaluate 
the ONJ expansion in conjunction with what is clinically 
observed inside the mouth. Special attention shall be paid 
to the possible existence of osteolysis areas, attributable to 
the basal disease.
- Make a microbiological culture and antibiogram of the 
exposed bone.
A.3. Histological diagnosis 12.506.
- In case of doubts in the differential diagnosis between ONJ 
and affectation due to basal disease, a bone biopsy shall be 
used, given that it is the definite test.
2.B. TREATMENT OF PATIENTS WITH ONJ.
For the treatment of  the OSTEONECROSIS area(s) a 
distinction shall be made between two situations in terms 
of the expansion of the lesion:
B.1. Patients with small ONJ areas.
A “conservative treatment” shall be initiated.
Based on the microbiological analysis, establish a treatment 
for 10-15 days with the appropriate antibiotic, in parallel 
with chlorhexidine rinses (once every 12 hours for a month). 
In case of a normal flora, it is recommended to use 875 / 125 
mg of amoxicillin / clavulanic acid or clindamycin.
- The healthcare professional should carry out irrigation of 
the exposed necrotic bed. 
with 0.12% chlorhexidine - once every 72 hours for four 
weeks. After one month, the patient should be reevaluated; 
two possibilities exist:
a. If  an improvement is confirmed the patient should conti-
nue with the 0.12% chlorhexidine rinses for another month 
of follow-up, both for the patient’s daily applications and 
the professional’s application every 72 hours.
b. In case there is not a good response to the conservative 
treatment, the said treatment shall be maintained for ano-
ther month. If, this period has elapsed but there is still no 
improvement, then the regimen stipulated in section B.2 
should be followed.
B.2. Patients with large ONJ areas and patients who have not 
evolved satisfactorily following a conservative treatment.
- Plan a surgical procedure to remove the area of the ne-
crotic bone (the expansion and magnitude of the surgical 
procedure will depend on the size of the ONJ).
- In case of ONJ presence, bisphosphonates treatment shall 
be suspended, being up to the physician to reintroduce it in 
case of an active bone disease, evaluating the risk / benefit ra-
tio. Corticoids withdrawal should also be evaluated, in case 
they had been administered as a maintenance therapy.
2.C. PHARMACOVIGILANCE INFORMATION
It is recommended to physicians to notify any ONJ suspi-
cion to the Pharmacovigilance Center of the corresponding 
Autonomous Community.
In case this happens during the treatment with Aredia® 
or Zometa®, Novartis Pharmaceuticals, S.A. can also be 
notified: by tel. +34 900 35 30 36 or fax +34 93 306 44 12.
3. CANCER AND BONE LESION
Bone remodeling in adults is an active process and, nor-
mally, osteoclasts activity is equal to that of osteoblasts. 
Nevertheless, in situations of alteration of the bone me-
tabolism, like in malignant bone metastases and multiple 
myeloma, an increase of  the osteoclastic activity causes 
bone resorption.
Bone metastases are a common cause of morbidity in pa-
tients with many types of cancer and they can cause pain, 
hypercalcemia, pathologic fractures, and spinal cord com-
pression. They are quite frequent in patients with breast, 
prostate or lung cancer. Hypercalcemia, associated with 
malignancies, represents around 45% of the total hyper-
calcemia cases.
It is the most frequent potentially mortal metabolic com-
plication among malignancies.
3.A. ADVANCED BREAST CANCER.
Breast cancer is the most common malignancy in the fe-
male sex and it is the main mortality cause due to cancer 
in European women.
The bone is the most frequent site for metastases in breast 
cancer patients. Almost 80% of the patients deceased due to 
a breast malignancy present bone dissemination, while this is 
also the most common site of disease recurrence, following 
a primary treatment against breast cancer.
Breast cancer expansion to bones can lead to significant 
morbidity in patients suffering from it. Events related to 
the complications secondary to the bone disease progres-
sion include: pain appearance, hypercalcemia, risk of bone 
fractures, risk of appearance of a medullary compression 
syndrome, and the need for radiotherapy administration. 
All this could limit patients’ mobility and, in short, reduce 
their quality of life.
Breast cancer treatment is palliative, and its main objective is 
to achieve the improvement of the patient’s symptoms and of 
her quality of life. Systemic treatment with chemotherapy or 
hormone therapy could accomplish this, although the intro-
duction of bisphosphonates, in the last few years, has offered 
a greater confidence to this end. Lytic metastasis of breast 
cancer are the result of an increased activity of osteoclasts 
reabsorption. Such process is mediated by various molecules, 
among which the following: tumor necrosis factor beta (TNF-
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ß) and interleukins 1 and 6. The development of treatments 
with osteoclast inhibitors, like bisphosphonates, offer a new 
dimension to the control of the symptoms and the prevention 
of skeletal complications. Bisphosphonates, especially third 
generation ones, like zolendronic acid, are potent osteoclast 
inhibitors (they delay maturation and induce the apoptosis 
of the osteoclasts with evident clinical effects), and they have 
allowed to improve patients’ symptoms, to reduce the risk of 
pathological fractures, or the need for antalgic radiotherapy. 
On the other hand, various in vitro studies suggest that bis-
phosphonates have an antitumor effect and this way they be 
in synergy with chemotherapy. Such effect has been used as a 
basis in the design of bisphosphonates studies as an adjuvant 
treatment for breast cancer, to avoid or delay the appearance 
of bone metastases.
3.B. MULTIPLE MYELOMA
Multiple Myeloma (MM), is a malignancy derived from B-
lymphoid cells in the last stage of maturation (plasma cells, 
PC) that, from a clinical point of view, is characterized by 
the triad of anemia, bone lesion, and renal insufficiency; 
while from a biological point of view, it is characterized by 
the presence of either a serum or urine monoclonal com-
ponent or both, and medullary plasmacytic infiltration. It 
is the second most frequent malignant hemopathy, with an 
incidence of 56 new cases for every million of inhabitants 
per year. The presence of bone lesions is a typical finding 
in MM patients, and they are visible through conventional 
X-rays in 80% of the cases, which can reach 96%, if  they 
techniques like NMR or PET are used. Bone lesions are 
produced due to an imbalance between bone resorption and 
formation in two phases. In early stages, there is an increase 
in resorption due to the osteoclast activation, secondary 
to the RANK / RANK-L hyperactivity. At first, the des-
tructive increase is compensated for with an increase in the 
bone formation, although, during the tumor clone growth, 
DKK1 gets synthesized: a factor inhibiting osteoblasts. This 
causes a loss of a net bone mass, and another triad appears: 
bone pain, fractures, and hypercalcemia. This mechanism 
of bone lesion generation constitutes the basis for the use 
of  bisphosphonates inhibiting bone resorption and thus 
contributing to the re-equilibration of the bone metabolism, 
improving patients’ bone lesion.
3.C. BISPHOSPHONATES AND PROSTATE CAN-
CER 
The clinical evolution of the bone metastases in prostate 
cancer is relatively long, with the appearance of skeletal 
complications for various years. Such skeletal complications 
include pain, fractures, hypercalcemia, and spinal squeezing, 
actively influencing in patients’ quality of life.
It is known that the main treatments administered to pa-
tients with advanced cancer include radiotherapy, systemic 
hormone therapies and cytotoxical treatments. Nevertheless, 
the use of bisphosphonates represents a new strategy as an 
additional treatment for the reduction of skeletal symptoms 
and complications.
Androgenic deprivation or Androgen Blocking (AB) is the 
standard treatment for disseminated prostate cancer. Never-
theless, currently, it also forms part of the high risk localized 
prostate cancer treatment, and it is the first or second line 
rescue treatment after low or medium risk localized prostate 
cancer radical treatment fails. Currently, it is estimated that a 
patient diagnosed with prostate has a 60% chance to receive 
AB throughout his life.
Precedents of  skeletal fractures are an independent pre-
dictive factor of  minor survival rates in patients with 
prostate cancer subjected to an AB; moreover, it suggests 
deterioration of the quality of life from the moment of the 
fracture. Prostate cancer patients run a higher risk of bone 
fracture, as a consequence of the bone fragility secondary 
to the metastases or the bone mass loss secondary to the 
AB with LH-RH analogues (entails a suppression of the 
testosterone serum levels similar to those of surgical cas-
tration) or both. 
Incidence of skeletal osteoporotic fractures, as well as the 
increase in the relative risk of suffering them is relevant to 
AB; their duration or the number of LHRH analogues doses 
administered, or both.
Various clinical studies carried out with zolendronic acid 
have offered evidence on the clinical usefulness of this bis-
phosphonate, in patients with advanced prostate subjected 
to an AB, basing its efficacy on the results obtained and 
published on:
1. Avoiding and significantly delaying (vs. placebo) skeletal-
related events (SRE) in patients with bone metastases.
2. Relieving pain and improving patient’s mobility at rest 
and in motion.
3. Preventing bone mass loss and treating osteoporosis.
Calcium and vitamin D supplements have been normally 
used in combination with bisphosphonates and in the control 
groups of the clinical trials. Their individual use can prevent 
the bone mass loss in patients subjected to an AB. Moreover, 
it has been observed that inadequate calcium ingestion has 
been associated with the presence of osteoporosis in prostate 
cancer patients, either subjected to an AB or not. 
4. BISPHOSPHONATES
Bisphosphonates constitute a group of compounds and their 
structure is based on that of pyrophosphate: a compound that 
regulated precipitation and extraction of minerals from the bone, 
albeit they are sensitive to phosphatase hydrolysis. Bisphospho-
nates change the structure through a phosphorus-carbon-phos-
phorus axis, which is very stable and resists enzyme hydrolysis, 
which thus allows a strong bound to the bone. Bisphosphonates, 
thanks to their capacity to inhibit osteoclastic activity, are the 
standard treatment for tumor-related hypercalcemia, and they 
have been proven to reduce bone pain, improve quality of life, 
delay skeletal events, and decrease their number.
ZOLEDRONIC ACID.
Description: zolendronic acid is the active ingredient of 
Zometa®. It is an IV administered aminobisphosphonate. 
Zometa® has been marketed since August 2002.
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Action: zolendronic acid is rapidly bound to the bone, inhi-
biting osteoclastic activity, and thus improving bone resorp-
tion. Its selective bone action is based on its great affinity 
for bones at remodeling phase. Obviously, zolendronic acid 
inhibits bone resorption without affecting bone formation, 
mineralization or mechanical properties.
Indications:
- Prevention of  skeletal complications associated to the 
myeloma bone lesion (pathological fractures, medullary 
compression, need to use bone irradiation or surgery, and 
tumor-induced hypercalcemia), in patients with advanced 
malignancies with bone affectation.
- Treatment of tumor-induced hypercalcemia (TIH).
Dosing and administration: the recommended dose for 
the prevention of events related to the skeleton in multiple 
myeloma 4 mg of Zometa®, administered as a 15-minute 
IV perfusion every four weeks.
Recommendations included in the technical file: patients 
with cancer should be subjected to a dental revision before 
initiating treatment with intravenous bisphosphonates. 
Avoid dental procedures while on treatment with bisphos-
phonates, since in patients who might develop an ONJ 
during the bisphosphonates treatment, dental surgery could 
exacerbate this situation. In case a patient needs a dental 
procedure, there are no data available suggesting that the 
interruption of the treatment with bisphosphonates reduces 
the risk of osteonecrosis of the jaw.
5. GENERAL RECOMMENDATIONS ON THE 
USE OF BISPHOSPHONATES IN PATIENTS 
WITH MALIGNANCIES
- Currently, there is evidence of the usefulness of the ad-
ministration of bisphosphonates for a two-year period. As 
of that moment, international experts’ recommendations 
are controversial, especially because there is no scientific 
evidence on their unlimited administration in en patients 
with an inactive or plateau phase of the disease.
- Some groups advocate that, after two years of treatment, 
it could be continued with an administration regimen of 
every three to four months. Nevertheless, such regimen has 
not yet been proved by scientific evidence.
- In case of recurrence in patients who have taken bisphos-
phonates for two years but then their treatment has been 
interrupted, it shall be necessary to consider the reintroduc-
tion of the drug, especially if  there is bone symptomatology 
or alterations in calcium metabolism.
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